GENELUX Corp — Director's Dealing 2023

Sep 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GENELUX Corp (GNLX)
CIK: 0001231457
Period of Report: 2023-09-26

Reporting Person: Yu Yong (VP, Clinical Trial Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-26	Common Stock	M	5200	$6.00	Acquired	111335	Direct
2023-09-26	Common Stock	S	1883	$22.5397	Disposed	109452	Direct
2023-09-26	Common Stock	S	1114	$23.5145	Disposed	108338	Direct
2023-09-26	Common Stock	S	2203	$24.4623	Disposed	106135	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-26	Stock Option (right to buy)	$6.00	M	5200	Disposed	2029-09-20	Common Stock (5200)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023.

F2: The weighted average sale price for the transaction reported was $22.5397, and the range of prices were between $22.13 and $23.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: The weighted average sale price for the transaction reported was $23.5145, and the range of prices were between $23.16 and $24.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F4: The weighted average sale price for the transaction reported was $24.4623, and the range of prices were between $24.24 and $24.755. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F5: Immediately exercisable.